Equities analysts expect TG Therapeutics, Inc (NASDAQ:TGTX) to report earnings of ($0.55) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for TG Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.58). TG Therapeutics reported earnings of ($0.45) per share in the same quarter last year, which would indicate a negative year over year growth rate of 22.2%. The company is expected to report its next earnings results on Wednesday, August 8th.
According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.36) to ($1.34). For the next year, analysts forecast that the company will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.66). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.15). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 87,025.00% and a negative return on equity of 170.83%.
NASDAQ:TGTX opened at $14.05 on Friday. TG Therapeutics has a 1 year low of $13.48 and a 1 year high of $13.80. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -7.36 and a beta of 1.21.
Large investors have recently added to or reduced their stakes in the business. Senzar Asset Management LLC increased its stake in TG Therapeutics by 56.9% in the 4th quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock worth $11,112,000 after acquiring an additional 491,678 shares during the last quarter. CIBC World Markets Inc. bought a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $250,000. University of Notre Dame DU Lac bought a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $2,483,000. Allianz Asset Management GmbH increased its position in shares of TG Therapeutics by 6.6% during the 4th quarter. Allianz Asset Management GmbH now owns 137,980 shares of the biopharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 8,602 shares during the last quarter. Finally, Dupont Capital Management Corp increased its position in shares of TG Therapeutics by 153.1% during the 4th quarter. Dupont Capital Management Corp now owns 64,957 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 39,295 shares during the last quarter. 47.35% of the stock is currently owned by institutional investors and hedge funds.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.